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Abstract
The CellScan apparatus is a laser scanning cytometer enabling repetitive ﬂuorescence intensity (FI) and polarization (FP)
measurements in living cells, as a means of monitoring lymphocyte activation. The CellScan may serve as a tool for diagnosis
of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) as well as other autoimmune diseases by monitoring FP
changes in peripheral blood lymphocytes (PBLs) following exposure to autoantigenic stimuli. Changes in FI and FP in
atherosclerotic patients’ PBLs following exposure to various stimuli have established the role of the immune system in
atherosclerotic disease. The CellScan has been evaluated as a diagnostic tool for drug-allergy, based on FP reduction in PBLs
following incubation with allergenic drugs. FI and FP changes in cancer cells have been found to be well correlated with the
cytotoxic effect of anti-neoplastic drugs. In conclusion, the CellScan has a variety of applications in cell biology, immunology,
cancer research and clinical pharmacology.
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Introduction
The CellScan apparatus is a laser scanning cytometer
incorporating a unique cell carrier that allowsrepeated
high-precision ﬂuorescence intensity (FI) and polar-
ization (FP) measurements to be made on intact living
cells under physiological conditions (Zurgil et al.
1999a). The ﬁxed location of the cells in the carrier
permits kinetic measurements, re-measurement after
reaction with a stimulant or drug, or monitoring the
same population under a different machine set-up
(Kaplan et al. 1997). Reviewed here are the different
implementations of the CellScan system in immuno-
logy, cell biology, cancer research and clinical
pharmacology.
The processes linking early and late intracellular
events in the course of cell activation and apoptosis
involve conformational changes of cytosolic enzymes
and/or their regulatory proteins, as well as their
intracellular matrix reorganization. The monitoring of
these early and structural changes can be preformed
by measuring the FP of intracellular ﬂuorescence
probes (Deutsch et al. 2000). Among these probes is
ﬂuorescein diactetate (FDA), a non-ﬂuorescent
molecule that undergoes ﬂuorochromasia in viable
cells. This includes penetration of FDA, its enzymati-
cal hydrolysis, which converts it to ﬂuorescein, and the
accumulation of the latter (Zurgil et al. 1996).
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the level of freedom of the intracellular dye, due to its
interaction with various cellular components in
different intracellular oraganelles (Fixler et al. 1997).
The more the molecule rotational movement is
restricted, the higher the FP value, and vice versa. If
molecules are free to change their orientation
randomly, then due to the time lapse between
excitation and emission, the polarization of the
ﬂuorescence relative to the excitation light changes
randomly, and decreases (Zurgil et al. 2002). Changes
in FP have been detected concurrently with physical
alterations of the cells: Changes in osmolarity, cell
stimulation, apoptosis and progression through cell-
cycle phases (Deutsch et al. 2000).
The CellScan apparatus
The CellScan apparatus was developed with the
objective of enabling repetitive FP measurements on
individual cells. The apparatus has three principal
components:
(a) A cell carrier, consisting of a grid of precisely
dimensioned and contoured microscopic holes
on a ﬂat surface, which captures cells of a desired
size and holds them in place for repeated
measurements. The carrier, used for lympho-
cytes, has holes 5–8mm in diameter, spaced
20mm apart; a 2-mm squared grid can hold
10,000 cells, each loaded in a separate trap
(Figure 1).
(b) A motor-driven, microscopic stage that holds and
moves the cell-carrier.
(c) A micro-photometer comprised of a blue laser
light source, microscopic optics for illuminating
the sample and collecting ﬂuorescent light, and
four photomultiplier tubes and associated optical
and electronic equipment for measuring FP at
two wavelengths.
Three parameters are considered in measuring
ﬂuorescence emissionfrom cells: FI,FP,and measure-
ment time (t). Classiﬁcation of subgroups of cells may
be based on any of these parameters. Acquired data is
displayed on-line, both graphically and numerically
(Figure 2). The software determines all test limits,
before, during and after the scan. All on-line statistics
are displayed during the test, as well as numerous
numerical and graphic screens, e.g. historgrams and
scatter diagrams (Deutsch et al. 2000).
Monitoring lymphocyte biology
FP of Jurkat T-lymphocytes has been demonstrated to
be cell-cycle dependent. Phase selection was achieved
either by differential cell densities or phase-arresting
drugs such as hydroxyurea and noconazole. As the cell
Figure 1. An electron micrograph of lymphocytes trapped on the
Cellcarrier.
Figure 2. Scatter plots of FI (vertical axis) vs. FP (horizontal axis)
of control (A) and PHA-treated lymphocytes (B). The drop in
average FP (marked P in the center of the ﬁgure) of PHA-treated
lymphocytes is observable.
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G0/G1 stages had increased, a concomitant and
signiﬁcant increase in FP was observed. Both
hydroxyurea mediated S phase arrest and noconazole
mediated G2/M arrest induced a reduction in FP.
Thus, FP is cell-cycle dependent with signiﬁcantly
lower values for cycling than for non-cycling
populations (Zurgil et al. 1996).
It has been established that thiols are of prime
importance to the functional performance of lympho-
cytes. The CellScan apparatus in conjunction with the
probe chloromethyl ﬂuorescein diacetate (CMFDA),
have been used to monitor thiol levels in individual
cells responding to a variety of experimental con-
ditions. The analysis of FPof intracellular ﬂuorophore
ﬂuorescence signals has been used as a tool for
discriminating between unconjugated 5-chloromethyl
ﬂuorescein (CMF), the hydrolyzed product of
CMFDA, and a thiol bound adduct. Also,the covalent
conjunction of intracellular ﬂuorescent molecules to
sulphydryl residues was revealed by the use of the FP
ratio. The proportion of SH-F adduct and the
unconjugated CMF in the cell has been found to be
modulated by parameters such as CMFDA concen-
tration, staining duration as well as the elapsed time
following the cessation of the staining process. An
increase in intracellular thiol levels has been observed
during cell proliferation, attributed to the oxidative
activity following stimulation (Zurgil et al. 1999b).
Monitoring lymphocyte activation
T-cell stimulation is an induced physiological process
of major importance in a wide range of immunological
responses. It involves a cascade of biochemical and
biophysical cellular events initiated by antigen
recognition followed by transmission of signals to the
nucleus, ultimately leading to proliferation (Kaplan
et al. 1997).
Studies have shown that lymphocyte activation is
accompanied by alterations in the structuredness of
the cytoplasmic matrix (SCM) causing changes in FP.
Traditionally, T-cell activation is assayed by determin-
ing lymphoblast formation in culture, by measuring
the incorporation of radioactive DNA precursors.
Another means has been the monitoring of cyto-
plasmic Ca
þþ increase following stimulation. FP
monitoring has advantages over both methods; Unlike
DNA precursor incorporation that measures cell
proliferation commencing 24h after stimulation,
changes in FP appear at a very early stage of
stimulation (50min within onset of stimulation).
Also, while elevated [Ca
þþ]i is transient and difﬁcult
to follow, FP changes are stable for hours.
Using the CellScan, the alterations in SCM
following stimulation were measured by monitoring
FP of FDA-labeled cells. Exposure of T-lymphocytes
to polyclonal proliferation inducers, such as the lectin
phytohaemagglutinin (PHA), has been shownto cause
a concentration-dependent decrease in FP (Kaplan
et al. 1997).
Using this stimulation method, it has been found
that cells within a mixed population can be
distinguished both by their individual FI and by FP
kinetics. Although great variance was noted, a
characteristic phenomenon was observed in which
the cell-staining rate may be divided into three major
subgroups: low (L), medium (M) and high (H).
AdecreaseinFPinducedbyPHAwasmostprominent
in the low subgroup, while the high subgroup did not
showsuchchanges,andevenyieldedanincreaseinFP.
All groups showed a decrease in FP values over time,
but while the L subgroup quantitatively conserved
ﬂuorescence depolarization (FDP), in the other
subgroups (H and M) the FDP decreased or even
changed sign. The distinction between these three
groups is therefore important in the prediction of FP
changes following stimuli (Sunray et al. 1999).
A similar decrease in FP was observed in
lymphocytes exposed to concanavalin (ConA) and
pokeweed mitogen (PWM), T and B-lymphocytes
stimulants, respectively, although to a lesser extent
than following PHA incubation, as represented by the
length of the incubation period and the minimal
concentration needed for stimulation.
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lymphocytes after incubation with anti-CD3 antibody
(Eisenthal et al. 1996), and in lymphocytes exposed to
phorbol 12-myristate 13-actetate (PMA), a phorbol
ester which activates protein kinase C (PKC). This
last ﬁnding suggests the decrease in FP upon
stimulation reﬂects intracellular changes in the path-
way of PKC induction (Kaplan et al. 1997).
Using the CellScan, the biological signiﬁcance of
changes in FP in PBLs exposed to PHA and anti-CD3
has been further investigated. It has been established
that the extent of polymerization of the cytoskeleton
microtubules and microﬁlaments is affected during
cell activation. Therefore, cytochalasin B, a microﬁla-
ment structure modulator, as well as vinblastine and
cholchicine, which both affect the microtubules, were
employed in order to analyze their effect on FP of
stimulated cells. Colchicine, vinblastine and cytocha-
lasin B added to PHA or anti-CD3 stimulated PBLs
have been shown to reverse the effect of these
stimulants on FP, as well as inhibit DNA synthesis.
The similarity bywhich these cytoskeleton modulators
affected both skeleton polymerization and cell
proliferation points toward the possible role of the
cytoskeleton in signal transduction, as well as further
establish their role in cell activation (Eisenthal et al.
1996).
A similar research using human lung ﬁbroblasts
has shown that exposure of the ﬁbroblasts to
interleukin 1a, interleukin 1b and tumor necrosis
factor a, which are known to be ﬁbroblast-cell
Applications of the CellScan, a static ﬂuorescence-based cytometer 189activators as well as modulators of immune responses,
induced a decrease in FP. This effect was reversed in
the presence of vinblastine and cytochalasin (Marder
et al. 1996), suggesting that the role of microtubules
and microﬁlaments in cell activation is not lympho-
cyte-speciﬁc, but rather a common denominator of
cell activation.
It has been demonstrated that infection of human
PBLs with inﬂuenza A virus, a known modulator of
the immune response, reduces FP. It has been
suggested that viral infection induces cellular acti-
vation, which affects the cytoskeleton. In addition to
the effect observed in resting PBLs, inﬂuenza A virus
has synergistically decreased FP following exposure to
PHA, further establishing the role of the virus as a
cytoskeletal modulator. The decrease in FP induced
by the virus has also lead to an increase in cell
proliferation following incubation with PHA, com-
pared to non infected cells, in a dose-dependent
manner. These results conﬁrm the effect of the virus
on cell activation via modulation of the cytoskeleton.
The mechanism by which the inﬂuenza virus alters
the cytoskeleton is yet unknown. One possibility is that
viral proteins, induced during infection, affect mono-
meric G actin, thus affecting cytoskeletal polymeriz-
ation. This hypothesis is supported by the correlation
between the kinetics of FP changes and the time range
of H1 viral protein induction (Eisenthal et al. 1997).
Recombinant soluble peptide-single-chain major
histocompatibility complex (MHC) tetramers are
valuablereagentsfor characterizing immuneresponses
involving T cells. The CellScan has been used to
monitor the binding of melanoma speciﬁc-MHC
tetramers to T-cells through monitoring of FI,
complemented by the assessment of changes in FP,
to detect the response of T lymphocytes. The ﬁndings
were well correlated with lymphocyte binding and
stimulation as conﬁrmed by FACS analysis and INF-g
release test, respectively. The ability to monitor both
binding and lymphocyte stimulation makes the
CellScan system a useful tool in detection of
responsive T-cells in various immunological settings
(Cohen et al. 2003).
Monitoring of effector and target cell interaction
FP measurements have been used to demonstrate
prelytic intracellular changes induced in target and
effector cells following conjugation at room tempera-
ture. It has been shown that conjugation of K562 cell
lines with natural killer (NK) cells or with lymphocyte
activated killer (LAK) cells yielded a decrease in FP.
These results were in agreement with the results
obtained using the Chromium release assay used to
monitor cell-killing activity of NK and LAK cells. The
ﬁndings were also consistent with the expression of
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and target cell interaction (Fixler et al. 1998).
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cytoskeletal changes in target and effector cells
infected by infulenza A virus. It has been shown that
infection of both K562 target cells and NK effector
cells causes an increase in cell lysis. This increase has
been well correlated with an increase of ICAM-1
expression. FP measurements have shown changes in
the cytoskeleton following infection of K562 cells by
inﬂuenza A virus, indicating the involvement of such
changes in the regulation of NK lysis. One possibility
is that the cytoskeletal changes may result in
reorganization of ICAM forming a uropodson, a
bud-like cellular projection, which may render NK
target cells more susceptible to killing through this
ligand (Eisenthal et al. 1997).
Separate speciﬁc staining and FP monitoring of
effector and target cells shows early reciprocal and
speciﬁc stimulation responses of K562 cells in
conjugation with NK/LAK cells. These measurements
also indicate the time-dependent nature of stimu-
lation. Two phases were described. In the ﬁrst phase, a
marked sharp depolarization followed by a slow
repolarization was observed in both the target and
effector cells. In the second phase, the FP of the
effector cell remains in its control value while that of
the target cell continuously decreases. While the ﬁrst
phase is attributed to conjugation-related stimulation
of both cells, it is suggested that the second phase
indicates the target cell commitment to a lethal
trajectory. The kinetics of FP measurements indicate
that the stimulation of NK cells due to conjugation
precedes the reciprocal stimulation of K562 cells by a
few minutes, later becoming lethal.
Also, these results are consistent with a dynamic
structural orientation of intracellular components
during cell activation, indicating an initial reciprocal
orientation followed by a vertical one (Fixler et al.
1997).
Monitoring apoptotic events
Apoptosis, or regulated cell death, is a physiological
elimination process of damaged or unwanted cells,
which ensures equilibrium between cell proliferation
and death. While a low level of apoptosis has been
linked to malignancies, resistance to anti-cancer
drugs, and autoimmune diseases, a high level of
apoptotic activity can result in immune deﬁciency and
degenerative conditions. Hence, the measurement of
cellular apoptotic activity has become a matter of great
importance in the diagnosis and monitoring of these
conditions (Zurgil et al. 2000).
Evidence has been provided that the hyper polariz-
ation(HP)ofintracellularﬂuoresceincanbeutilizedas
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The increase in the FP parameter was found to be
ubiquitous, since it was demonstrated in several well-
knownmodelsofcellsundergoingapoptosisbyvarious
agents (i.e. serum-deprived and dexamethasone
treated Jurkat T cells, cultured, dexamethasone and
anti-Fas treated mouse thymocytes).
The intracellular HP coincides with morphological
changes observed by a light diffraction cytometer.
A direct correlation was found between the
FP changes and the decrease in cell diameter.
In addition, a decrease in FI was measured
concurrently with FP changes of apoptotic cells.
HP in FDA labeled cells has been shown to appear
earlier than the phosphatidylserine exposure and to
be a more sensitive measure for early apoptosis
in both mouse thymocytes and Jurkat T-cells (Zurgil
et al. 2000).
Ithasbeenfoundthatthecytoplasmiccondensation,
reﬂected by the increase in FP, preceded other
functional apoptotic parameters. The change in
intracellular FP can be modulated by osmolarity
changes in the medium, suggesting that cell dehy-
dration and shrinkage may be involved in the
phenomena of intracellular ﬂuorescein HP in apopto-
sis. Caspase inhibitors exhibited effect neither on HP
nor on volume decrease during the early stages of
apoptosis, suggesting that cell shrinkage precedes
caspase activation.
Measurements of changes in FI of the ﬂuophore
acridine orange (AO) at two wavelengths indicated
early alterations in lysosomal stability in Jurakt cells
subjected to mild oxidative stress. These ﬁndings
support the information regarding the involvement of
lysosomal rupture in oxidative stress induced apopto-
sis (Zurgil et al. 2002).
FP measurements have been used to monitor
apoptotic processes induced by oxidized low-density
lipoprotein (oxLDL) in T-lymphocytes and mono-
cytes cell-lines. OxLDL, which plays a key role in
atherogenesis, has been found to be cytotoxic to both
cell types, in a time- and dose-dependent manner.
These ﬁndings have been demonstrated by early
cytoplasmic condensation resulting from cell shrink-
age, as measured by an increase in FP of ﬂuorescein-
labeled cells. The radical scavenger, superoxide
dismutase (SOD), reduced the effect of ox-LDL in a
time- and dose-dependent manner. The hyperpolar-
ization of ﬂuorescein-labeled cells has preceded the
appearance of phosphatidylserine on the plasma
membrane. FP measurements have detected different
cell death kinetics, as well as varying sensitivity to the
inhibitory effect of SOD in monocytes and lympho-
cytes, suggesting that reactive oxygen species gener-
ation are involved in ox-LDL-induced apoptosis. It
has also been demonstrated that monocytes are more
susceptible to cell death triggered by oxidative stress.
Thus, FP measurement may serve as a research tool in
the pathogenesis of atherosclerosis, speciﬁcally
through apoptotic cell death (Zurgil et al. 2004).
Analysis of enzyme kinetics
The CellScan ability to monitor time kinetic events
through repetitive measurement has been employed in
the study of intracellular enzymatic kinetics. The
apparatus was used to monitor the esterase hydrolysis
of two ﬂourogenic substrates, FDA and CMFDA,
which differ in their kinetics. The FI curve of FDA-
labeled cells was used to calculate the Michaelis-
Menten constant Km, which was similar in different
cell populations. Such similarity was not found in FI
curves of CMFDA-labeled cell populations, although
their FP kinetic behavior was very similar. FI depends
on many variables, irrelevant of the enzymatic process.
Therefore, measuring FP may be used as an additional
tool to monitor enzymatic processes, and thus
contribute to their understanding (Deutsch et al.
2000).
Monitoring the FI kinetics of the FDA enzymatic
hydrolysis was also applied to trace differences in
distributions of Km and Vmax over a population of
individual lymphocytes that were incubated with or
without the mitogen PHA. It has been found that
average Km and Vmax values profoundly increase
following PHA-stimulation. These changes in Km and
Vmax have appeared to be entirely due to an increase in
the dissociation rate k2. This supposition is well
supported by both theory and experimental ﬁndings
concerning changes in intracellular pH, viscosity and
cell diameter upon stimulation. These ﬁndings further
establish the CellScan as a tool for assessing enzymatic
reaction kinetics (Sunray et al. 2002).
Such cellular enzymatic activity measurements have
been applied to the monitoring of breast cancer.
Steady state measurements of FI of FDA labeled cells
have been used to demonstrate the Km and Vmax of
peripheral blood cell esteraze-activity. A marked
difference in such enzymatic characteristics has been
shown between breast cancer patients and healthy
individuals following exposure to tumor tissue. In
addition, it has been found that higher Km values are
associated with a better prognostic status of breast
cancer (lymph node-negative tumors, hormone
receptor preservation, and the absence of Her-2/neu
protein over-expression). Thus, the Km and Vmax of
peripheral blood monocyte reactions may serve as
additional criteria for monitoring and prognosis of
breast cancer (Afrimzon et al. 2004).
Early cancer detection
Early detection of cancer is of crucial importance to
the patient’s life duration and quality, prognosis and
treatment options. FP measurement, or the SCM test,
has been ﬁrst suggested by Cercek and Cercek (1997)
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approach is based on the appearance of memory
lymphocytes in the circulation, which recognize
antigens expressed by tumor cells. Hence, exposure
of these memory cells to cancer-related antigens may
then induce stimulation detected by the changes in FP
(Merimsky et al. 1996).
It has been reported additionally that lymphocytes
respond to stimulation with a tumor-derived antigen
in an organ site-dependent fashion. PBLs from
patients with breast cancer show decrease in polariz-
ation following exposure to substances from breast
cancer tissue or cancer cells while not responding to
substances derived from colon or lung cancer. This, in
principle, should permit determination of the primary
site of tumors diagnosed by the SCM test. The SCM
test was controversial at ﬁrst due to technical
complexities that made its clinical application difﬁcult
(Deutsch et al. 1996). The CellScan apparatus
simpliﬁes and increases the precision of the FP
measurements, and also allows the analysis to be made
on lymphocytes isolated by a relatively simple
procedure (Rahmani et al. 1996), thus making the
SCM test a more clinically applicable option.
The SCM test and the CellScan have been shown to
distinguish between different neoplastic diseases-
patients and healthy controls. Among the neoplasms
studied were colorectal cancer (Merimsky et al. 1996),
breast cancer (Rahmani et al. 1996, Ron et al. 1995,
1996, Klein et al. 2002a, 2002b), prostate cancer
(Klein et al. 1999), malignant melanoma (Merimsky
et al. 1997), lung and ovarian cancer (Deutsch et al.
1996). In these studies, diagnostic algorithms have
been created, based on PBLs responses to different
antigenic stimuli. These stimulants include PHA,
cancer basic protein (CaBP), encephalogenic factor
(EF), and tumor-associated antigens (TAA) for the
detection of colorectal and breast cancer (Merimsky
et al. 1996, Deutsch et al. 1996, Rahmani et al. 1996).
No signiﬁcant stage-related differences were found in
the polarization values following stimulation by EF or
PHA in breast cancer patients (Ron et al. 1996). Also
used were CaBr (Ron et al. 1995) and MUC-1/SEC
(Klein et al. 2002a, 2002b), both tumor-associated
antigens speciﬁc for breast cancer, PSA-ACT, a
prostate speciﬁc antigen (Klein et al. 1999), MEL, a
melanoma antigen, as well as different tumor antigen
extracts (TAE) (Deutsch et al. 1996, Rahmani et al.
1996).
Using the diagnostic algorithms, sensitivity and
speciﬁcity values achieved have ranged between
60–97% and 80–98% respectively.
Monitoring autoimmune phenomena
T-lymphocytes with the capacity to respond to organ-
speciﬁc autoantigens, including anti-self T-cells with
pathogenic potential, are present in the normal
immune repertoire. These anti-self T-cells can be
activated by exposure both to the corresponding auto-
antigen and by co-stimulatory signals. It has been
found that such T-cells mediate autoimmune response
in some of the human autoimmune disorders (Zurgil
et al. 1997).
Rheumatoid arthritis (RA) is a multi system disease
associated with impaired cellular immune function.
Many studies have demonstrated the role of T-
lymphocytes in the pathogenesis of RA. Joint-derived
T-cells of RA patients were shown to react with self-
immunoglobulin heavy chains or immunoglobulin-
binding proteins. Using the CellScan, it has been
shown that incubation of PBLs derived from RA
patients with afﬁnity puriﬁed IgG resulted in a
reduction of FP. Kinetic analysis of the FP decay of
RA-lymphocytes has shown an exponential pattern
typical of resting lymphocytes prior to incubation with
IgG, and a linear pattern typical of PHA stimulated
lymphocytes following the incubation.
In addition, it has been shown that most of the
rheumatoid factor (RF)-negative patients could be
detected by testing with the CellScan apparatus.
Thus, the CellScan may allow better diagnosis and
disease monitoring of RA patients who are RF-
negative, a group which accounts for 25% of adult RA
patients and 90–95% of juvenile RA patients (Zurgil
et al. 1999c).
Systemic lupus erythematosus (SLE) is a systemic
autoimmune disease characterized by the production
of autoantibodies (autoAb) directed against cell-
surface, nuclear and cytoplasmic proteins. It has
been proven that nucleosomes are major autoantigens
for the pathogenic activation of Tand B-lymphocytes
in SLE. The analysis of sensitivity and speciﬁcity of
autoAb directed against native nucleosomes in
patients with autoimmune disease has demonstrated
high prevalence, clinical speciﬁcity, and diagnosis
conﬁdence in patients with SLE. Moreover, these
antibodies are linked to disease activity and may
contribute to the development of lupus nephritis. It
has been found that FP levels in FDA-stained cells of
SLE patients detected by the CellScan decrease
following stimulation by a nucleosomal autoantigen.
This ﬂuorescence depolarization was autoantigen-
speciﬁc and dose-dependent, as well as highly speciﬁc
for SLE-derived PBLs. Similar results were obtained
by proliferation assays. These ﬁndings underscore the
value of the CellScan in monitoring speciﬁc cell
response to nucleosomal antigen in SLE patients, thus
providing a means of monitoring disease activity and
response to therapy (Gilburd et al.).
Atherosclerosis is a histopathologic process charac-
terized by gradual accumulation of lipids in the vessel
wall with subsequent recruitment of smooth muscle
cells, T-lymphocytes and additional cellular com-
ponents. In recent years, considerable data has been
accumulated regarding the involvement of the
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suggested by the presence of immunocompetent cells
and immunoglobulin deposition in the vicinity of the
plaques, and by successful immunomodulation of the
atherosclerotic process.
OxLDL, which has been considered to be an
acceptable immunogen, is suspected to be one of the
target autoantigens that trigger the “ongoing” local
inﬂammatory reaction. The CellScan has been used to
monitor the reactivity of PBLs to oxLDL in
atherosclerotic patients and healthy controls.
Exposure of PBLs to high concentration of oxLDL
has lead to a decrease in FI and an increase in FP in
both atherosclerosis and control groups (Zurgil et al.
1999a). Such ﬂuorescent changes have been estab-
lished to be well correlated with apoptotic processes
(Zurgil et al. 2000), suggesting an apoptotic response
to the cytotoxic damage of oxLDL. In low concen-
trations of oxLDL, however, FP decreased and FI
increased in atherosclerosis-derived PBLs, suggesting
cellular stimulation. This dual effect of oxLDL,
namely depolarization at low dose and hyperpolariz-
ation at a higher dose, was evident in patients with
active ischemic heart disease, but not in the control
group (Zurgil et al. 1999a). One of the explanations
suggested is that lymphocytes of atherosclerotic
patients are more resistant to apoptosis by oxLDL
damage, therefore allowing their continuous role in
the inﬂammatory response. Nevertheless, the FP and
FI measurements provide a simple, non-invasive tool
of assessing atherosclerosis (Zurgil et al. 1999a).
Other target autoantigens suspected of generating
an immune response in the atherosclerotic plaque are
human b2 glycoprotein and heat shock proteins—
HSP 65, and lysophophatidylcholine (LPC). In vitro
stimulation of PBLs of patients with unstable (UA)
and stable angina (SA) pectoris with LPC resulted in
signiﬁcant activation as manifested by the prolifer-
ation assay as well as the CellScan FP measurements.
Similar results were obtained following incubation of
PBLs derived from UA and SA patients with b2
glycoprotein and mycobacterial HSP65. Such ﬁndings
were not observed in PBLs of the control group. These
ﬁndings demonstrate once more the possibility of
using the CellScan as a diagnostic and clinical-
assessment tool (Gilburd et al. in press).
Clinical pharmacology—monitoring drug
efﬁcacy and drug allergy
Adverse reactions to pharmaceutical and diagnostic
products constitute a major hazard in the practice of
medicine, and are responsible for substantial morbid-
ity and cost. In the vast majority of drug reactions,
diagnosis is based on clinical parameters and lacks
objective conﬁrmation. Currently, there are no highly
speciﬁc tests that are predictive either of the capacity
of novel compounds (drugs) to induce allergic
reactions, or of the susceptibility of individuals to
experience allergic reaction. Two of the conventional
in vitro assays used to diagnose drug-induced skin
reactions are the histamine-release test and the
interferon-g secretion test.
Using the CellScan, FPreduction in PBLs following
incubation with an allergenic drug has been moni-
tored. The sensitivity and speciﬁcity of the CellScan in
detecting drugs responsible for skin reactions have
been compared to those of the histamine-release test
and the interferon-g secretion test. The analysis of the
detective ability of the three tests, which was based on
clinical suspicion, has disclosed a low sensitivity
(41%) and speciﬁcity (69%) for the histamine-release
test, a relative high sensitivity (83%) and a moderate
speciﬁcity (76%) for the Interferon-g test, and a high
sensitivity (87%) and a moderate-low speciﬁcity
(53%) for the CellScan. The CellScan method has
been shown to have the highest sensitivity, while the
interferon-g secretion test has had the highest
speciﬁcity for the detection of the culprit drug.
However, the analysis of 105 normal control sera has
disclosed a high speciﬁcity of 94% for the CellScan.
These preliminary ﬁndings illustrate the CellScan as a
promising new method for the detection of drugs
responsible for adverse skin reactions (Goldberg et al.
in press).
Methotrexate (MTX) has been found to be the
preferred drug for RA patients. However, not all RA
patients respond to MTX, and those who do
experience an overall plateau of clinical response
only after six months of treatment. FP analysis has
been used as a method to predict the efﬁciency of
MTX treatment in RA patients through an in vitro
model. Considering the RA proﬁle of clonal-expanded
CD4þT-cells, PHA-activated mononuclear cells
taken from healthy donors were incubated with
different concentrations of MTX. The MTX-
immunosuppressive effect was tested by FP measure-
ments of the pre-incubated and FDA-stained cells as a
marker of activation or suppression. In healthy
activated mononuclear cells, it has been found that
MTX, through its early incubation period, interferes
with the activation signal obtained by PHA and exerts
an apoptotic signal, which is noted by the increase in
FP. This ﬁnding was conﬁrmed by PI assay, annexin V
assay, and ﬂow cytometry cell-cycle analysis, all
demonstrating the MTX cytotoxic and proliferation-
inhibiting effect.
FP analysis of RA patients-derived mononuclear
cells has shown a pattern of depolarization, as a
measurement of lymphocyte activation, and then
hyperpolarization as a measurement of an immuno-
suppressive effect. These ﬁnding demonstrate the
great potential of FP measurements as a tool for
predicting the efﬁciency of MTX in RA-patients, as
well as for making timing and dosage decisions
(Herman et al. 2003).
Applications of the CellScan, a static ﬂuorescence-based cytometer 193A major problem in clinical oncology is the
observation that neoplastic diseases classiﬁed identi-
cally, according to their histopathological character-
istics, often differ widely in their sensitivity to drugs.
Current cancer treatment is based on the results of
random trials preformed on patients with similar types
and stages of the disease. For reasons not well
understood, only a limited numberof patients respond
to a given chemotherapy protocol. In view of this
phenomenon, various chemosensitivity assays have
been developed in order to select the most effective
chemotherapy regimen and to avoid the toxicity of
potentially ineffective drugs. Clinical trials using these
assays, however, have not had a signiﬁcant impact on
patient survival.
The CellScan has been used to monitor FI and FP
changes in ﬂuorescently labeled cancer cells, in order
to investigate the effect of anti-neoplastic drugs on
human breast cancer cell-lines.
It has been shown that an increase in FP and a
concomitant decrease in FI are well correlated with
the cytotoxic effect of navelbine on T80 human breast
cancer cell-lines. This correlation was conﬁrmed by
the number of living cells following exposure to the
drug, as well as by apoptosis levels measured by the
Annexin V test, attributing the hyperpolarization
observed to drug-induced apoptosis.
Fluorescent hyperpolarization and reduced ﬂuor-
escent intensity were not observed in drug-resistant
cells, as was demonstrated in T47D human breast
cancer cell-lines following exposure to 5FU. These
ﬁndings further establish the ability of the CellScan to
differentiate between drug sensitivity and resistance in
cancer-cells.
Being independent of proliferation or colony-
formation assessment, the CellScan test does not
require the difﬁcult stage of tumor culturing, common
to many drug-sensitivity assays. This characteristic
enables more samples to be tested, each in a shorter
assay-time, thus making the CellScan a test of great
potential for the prediction of response and refractori-
ness of neoplastic tumors to chemotherapy (Schiffen-
bauer et al. 2002).
Summary
The CellScan apparatus may be used as a powerful
tool for cytometric studies. Its ability to monitor
ﬂuorescence changes in individual cells, as well as
kinetics of intracellular processes, creates a variety of
applications in cell biology, immunology, cancer
research and clinical pharmacology. The simplicity
and rapidity of the CellScan make it a promising new
method in both basic and clinical research.
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